Hypromed Injection contains Hydroxyprogesterone at a concentration of 250 mg/ml, a synthetic derivative of the naturally occurring hormone progesterone. It is primarily indicated for the prevention of preterm birth in pregnant women with a history of spontaneous preterm delivery. Hydroxyprogesterone acts by modulating the hormonal environment necessary to maintain pregnancy, thereby reducing uterine contractions and promoting uterine quiescence. The injection is administered intramuscularly, typically on a weekly basis, starting from the second trimester until 36 weeks of gestation or delivery, whichever occurs first. Hypromed Injection should be used under strict medical supervision, with careful consideration of the patient’s obstetric history and potential contraindications such as active thrombophlebitis, hepatic dysfunction, or known hypersensitivity to progestins. Common adverse effects may include injection site reactions, fluid retention, and mild gastrointestinal disturbances. Caution is advised in patients with a history of thromboembolic disorders or cardiovascular disease. The safety and efficacy of Hydroxyprogesterone in non-pregnant populations have not been established. Hypromed Injection is a valuable therapeutic option in obstetric care aimed at reducing the incidence of preterm labor and improving neonatal outcomes. Proper storage conditions and adherence to dosing schedules are essential to ensure optimal therapeutic effect.